Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3608MR)

This product GTTS-WQ3608MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3608MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ290MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ7603MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ5941MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ3775MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ3902MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ4838MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ15094MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ7578MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW